Latest stories on CAPR
Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)
PR Newswire28 · bearishgeneral
Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In
Stocktwits News34 · bearishgeneral
Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication ‘Reinforce Our Confidence’ For Approval
Stocktwits News73 · bullishproduct/pr
Lancet Validates Capricor’s HOPE-3 Duchenne Trial Results
TipRanks73 · bullishproduct/pr
CAPRICOR THERAPEUTICS, INC. (CAPR) files 8-K
SEC 8-K50 · neutralgeneral
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy | CAPR Stock News
StockTitan63 · neutralproduct/pr
CAPR INVESTIGATION: Capricor Therapeutics Investors Should Contact Block & Leviton About Recovering Their Losses
Business Insider34 · bearishgeneral
This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward
Stocktwits News28 · bearishanalyst
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount
Seeking Alpha28 · bearishanalyst
Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know
Seeking Alpha18 · bearishearnings
CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever
Stocktwits News48 · neutralgeneral
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’
Stocktwits News32 · bearishgeneral
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom
Investing.com Analyst Ratings34 · bearishgeneral
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target
Investing.com Analyst Ratings61 · neutralanalyst
B.Riley downgrades Capricor stock on FDA briefing concerns
Investing.com Analyst Ratings34 · bearishanalyst
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
Stocktwits News32 · bearishgeneral
Capricor Faces Critical FDA Advisory Meeting for Deramiocel—Company Defends Late-Stage Therapy Data Amid Scrutiny
July 27, 2026
MarketChameleon52 · neutralgeneral
Capricor Therapeutics Shares Slide on Negative FDA Comments
Morningstar28 · bearishgeneral
Oppenheimer reiterates Capricor stock rating ahead of FDA panel
Investing.com Analyst Ratings56 · neutralanalyst
Capricor plunges on FDA AdCom briefing doc for Duchenne treatment
Seeking Alpha28 · bearishproduct/pr
FDA staff flags data concerns about Capricor's therapy; shares plunge
Reuters28 · bearishgeneral
CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote
Stocktwits News28 · bearishgeneral